H.C. Wainwright lowered the firm’s price target on iTeos Therapeutics (ITOS) to $21 from $46 and keeps a Buy rating on the shares. The firm removed expected revenue from inupadenant in lung cancer following the interim data.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.